GPR119 and type 2 diabetes mellitus: Thus, the new GPR119 agonist ZB-16 demonstrated the mild hypoglycemic activity on glucose-loaded animals with the experimental type 2 diabetes mellitus caused by streptozotocin and nicotinamide administration.